Advancements in Autologous Stem Cell Transplantation for Parkinsons Disease
- Авторлар: Shi J.1, Zhang K.2
-
Мекемелер:
- Department of Neurology, The First Affiliated Hospital of Nanjing Medical University
- Department of Neurology, The First Affiliated Hospital of Nanjing Medical University,
- Шығарылым: Том 19, № 10 (2024)
- Беттер: 1321-1327
- Бөлім: Medicine
- URL: https://rjpbr.com/1574-888X/article/view/645455
- DOI: https://doi.org/10.2174/1574888X19666230907112413
- ID: 645455
Дәйексөз келтіру
Толық мәтін
Аннотация
:Parkinson's disease (PD) is a progressive neurodegenerative disease marked by comparatively focal dopaminergic neuron degeneration in the substantia nigra of the midbrain and dopamine loss in the striatum, which causes motor and non-motor symptoms. Currently, pharmacological therapy and deep brain stimulation(DBS) are the primary treatment modalities for PD in clinical practice. While these approaches offer temporary symptom control, they do not address the underlying neurodegenerative process, and complications often arise. Stem cell replacement therapy is anticipated to prevent further progression of the disease due to its regenerative capacity, and considering the cost of immunosuppression and the potential immune dysfunctions, autologous stem cell transplantation holds promise as a significant method against allogeneic one to treat Parkinson's disease. In this review, the safety concerns surrounding tumorigenicity and complications associated with transplantation are discussed, along with methods utilized to evaluate the efficacy of such procedures. Subsequently, we summarize the preclinical and clinical studies involving autologous stem cell transplantation for PD, and finally talk about the benefits of autologous stem cell transplantation against allogeneic transplants.
Негізгі сөздер
Авторлар туралы
Jia-Xin Shi
Department of Neurology, The First Affiliated Hospital of Nanjing Medical University
Email: info@benthamscience.net
Ke-Zhong Zhang
Department of Neurology, The First Affiliated Hospital of Nanjing Medical University,
Хат алмасуға жауапты Автор.
Email: info@benthamscience.net
Әдебиет тізімі
- McGregor, M.M.; Nelson, A.B. Circuit mechanisms of parkinsons disease. Neuron, 2019, 101(6), 1042-1056. doi: 10.1016/j.neuron.2019.03.004 PMID: 30897356
- Antonini, A.; Moro, E.; Godeiro, C.; Reichmann, H. Medical and surgical management of advanced Parkinsons disease. Mov. Disord., 2018, 33(6), 900-908. doi: 10.1002/mds.27340 PMID: 29570862
- Cury, R.G.; Pavese, N.; Aziz, T.Z.; Krauss, J.K.; Moro, E. Gaps and roadmap of novel neuromodulation targets for treatment of gait in Parkinsons disease. NPJ Parkinsons Dis., 2022, 8(1), 8. doi: 10.1038/s41531-021-00276-6 PMID: 35017551
- Hidding, U.; Gulberti, A.; Pflug, C. Modulation of specific components of sleep disturbances by simultaneous subthalamic and nigral stimulation in Parkinsons disease. Parkinsonism Relat. Disord., 2019, 62, 141-147. doi: 10.1016/j.parkreldis.2018.12.026 PMID: 30616868
- Tsui, A.; Isacson, O. Functions of the nigrostriatal dopaminergic synapse and the use of neurotransplantation in Parkinsons disease. J. Neurol., 2011, 258(8), 1393-1405. doi: 10.1007/s00415-011-6061-6 PMID: 21544566
- Parmar, M.; Grealish, S.; Henchcliffe, C. The future of stem cell therapies for Parkinson disease. Nat. Rev. Neurosci., 2020, 21(2), 103-115. doi: 10.1038/s41583-019-0257-7 PMID: 31907406
- Osborn, T.M.; Hallett, P.J.; Schumacher, J.M.; Isacson, O. Advantages and recent developments of autologous cell therapy for parkinsons disease patients. Front. Cell. Neurosci., 2020, 14, 58. doi: 10.3389/fncel.2020.00058 PMID: 32317934
- Tao, Y.; Vermilyea, S.C.; Zammit, M. Autologous transplant therapy alleviates motor and depressive behaviors in parkinsonian monkeys. Nat. Med., 2021, 27(4), 632-639. doi: 10.1038/s41591-021-01257-1 PMID: 33649496
- Piao, J.; Zabierowski, S.; Dubose, B.N. Preclinical efficacy and safety of a human embryonic stem cell-derived midbrain dopamine progenitor product, MSK-DA01. Cell Stem Cell, 2021, 28(2), 217-229.e7. doi: 10.1016/j.stem.2021.01.004 PMID: 33545080
- Morizane, A.; Takahashi, J. Evading the immune system: Immune modulation and immune matching in cell replacement therapies for parkinsons disease. J. Parkinsons Dis., 2021, 11(s2), S167-S172. doi: 10.3233/JPD-212608 PMID: 34024783
- Yousefi, N.; Abdollahii, S.; Kouhbanani, M.A.J.; Hassanzadeh, A. Induced pluripotent stem cells (iPSCs) as game‐changing tools in the treatment of neurodegenerative disease: Mirage or reality? J. Cell. Physiol., 2020, 235(12), 9166-9184. doi: 10.1002/jcp.29800 PMID: 32437029
- Fan, Y. Winanto, Ng SY. Replacing whats lost: A new era of stem cell therapy for Parkinsons disease. Transl. Neurodegener., 2020, 9(1), 2. doi: 10.1186/s40035-019-0180-x PMID: 31911835
- Shrigley, S.; Nilsson, F.; Mattsson, B. Grafts derived from an α-Synuclein triplication patient mediate functional recovery but develop disease-associated pathology in the 6-OHDA model of parkinsons disease. J. Parkinsons Dis., 2021, 11(2), 515-528. doi: 10.3233/JPD-202366 PMID: 33361611
- Schweitzer, J.S.; Song, B.; Herrington, T.M. Personalized iPSC-derived dopamine progenitor cells for parkinsons disease. N. Engl. J. Med., 2020, 382(20), 1926-1932. doi: 10.1056/NEJMoa1915872 PMID: 32402162
- Lanza, R.; Russell, D.W.; Nagy, A. Engineering universal cells that evade immune detection. Nat. Rev. Immunol., 2019, 19(12), 723-733. doi: 10.1038/s41577-019-0200-1 PMID: 31417198
- Giehrl-Schwab, J.; Giesert, F.; Rauser, B. Parkinsons disease motor symptoms rescue by CRISPRa‐reprogramming astrocytes into GABAergic neurons. EMBO Mol. Med., 2022, 14(5), e14797. doi: 10.15252/emmm.202114797 PMID: 35373464
- Takahashi, K.; Yamanaka, S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell, 2006, 126(4), 663-676. doi: 10.1016/j.cell.2006.07.024 PMID: 16904174
- Wang, H.; Yang, Y.; Liu, J.; Qian, L. Direct cell reprogramming: Approaches, mechanisms and progress. Nat. Rev. Mol. Cell Biol., 2021, 22(6), 410-424. doi: 10.1038/s41580-021-00335-z PMID: 33619373
- Zheng, W; Chen, Z Generation of induced neural stem cells from peripheral mononuclear cells and differentiation toward dopaminergic neuron precursors for transplantation studies. J Vis Exp, 2019, (149) doi: 10.3791/59690 PMID: 31355797
- Gugliandolo, A.; Bramanti, P.; Mazzon, E. Mesenchymal stem cell therapy in Parkinsons disease animal models. Curr. Res. Transl. Med., 2017, 65(2), 51-60. doi: 10.1016/j.retram.2016.10.007 PMID: 28466824
- Alizadeh, R.; Ramezanpour, F.; Mohammadi, A. Differentiation of human olfactory system‐derived stem cells into dopaminergic neuron‐like cells: A comparison between olfactory bulb and mucosa as two sources of stem cells. J. Cell. Biochem., 2019, 120(12), 19712-19720. doi: 10.1002/jcb.29277 PMID: 31297865
- Alizadeh, R.; Kamrava, S.K.; Bagher, Z. Human olfactory stem cells: As a promising source of dopaminergic neuron-like cells for treatment of Parkinsons disease. Neurosci. Lett., 2019, 696, 52-59. doi: 10.1016/j.neulet.2018.12.011 PMID: 30552942
- Alizadeh, R.; Bagher, Z.; Kamrava, S.K. Differentiation of human mesenchymal stem cells (MSC) to dopaminergic neurons: A comparison between Whartons Jelly and olfactory mucosa as sources of MSCs. J. Chem. Neuroanat., 2019, 96, 126-133. doi: 10.1016/j.jchemneu.2019.01.003 PMID: 30639339
- Staff, N.P.; Jones, D.T.; Singer, W. Mesenchymal stromal cell therapies for neurodegenerative diseases. Mayo Clin. Proc., 2019, 94(5), 892-905. doi: 10.1016/j.mayocp.2019.01.001 PMID: 31054608
- Venkataramana, N.K.; Kumar, S.K.V.; Balaraju, S. Open-labeled study of unilateral autologous bone-marrow-derived mesenchymal stem cell transplantation in Parkinsons disease. Transl. Res., 2010, 155(2), 62-70. doi: 10.1016/j.trsl.2009.07.006 PMID: 20129486
- Zakerinia, M.; Kamgarpour, A.; Nemati, H. Intrathecal autologous bone marrow-derived hematopoietic stem cell therapy in neurological diseases. Int. J. Organ Transplant. Med., 2018, 9(4), 157-167. PMID: 30863518
- Boika, A.; Aleinikava, N.; Chyzhyk, V.; Zafranskaya, M.; Nizheharodava, D.; Ponomarev, V. Mesenchymal stem cells in Parkinsons disease: Motor and nonmotor symptoms in the early posttransplant period. Surg. Neurol. Int., 2020, 11, 380. doi: 10.25259/SNI_233_2020 PMID: 33408914
- Duma, C.; Kopyov, O.; Kopyov, A. Human intracerebroventricular (ICV) injection of autologous, non-engineered, adipose-derived stromal vascular fraction (ADSVF) for neurodegenerative disorders: Results of a 3-year phase 1 study of 113 injections in 31 patients. Mol. Biol. Rep., 2019, 46(5), 5257-5272. doi: 10.1007/s11033-019-04983-5
- Carstens, M.; Haq, I.; Martinez-Cerrato, J.; Dos-Anjos, S.; Bertram, K.; Correa, D. Sustained clinical improvement of Parkinsons disease in two patients with facially-transplanted adipose-derived stromal vascular fraction cells. J. Clin. Neurosci., 2020, 81, 47-51. doi: 10.1016/j.jocn.2020.09.001 PMID: 33222965
- Shigematsu, K.; Komori, N.; Tahara, K.; Yamagishi, H. Repeated infusion of autologous adipose tissue‐derived stem cells for Parkinsons disease. Acta Neurol. Scand., 2022, 145(1), 119-122. doi: 10.1111/ane.13547 PMID: 34716582
- Henchcliffe, C.; Sarva, H. Restoring function to dopaminergic neurons: Progress in the development of cell-based therapies for parkinsons disease. CNS Drugs, 2020, 34(6), 559-577. doi: 10.1007/s40263-020-00727-3 PMID: 32472450
- Malat, G.; Culkin, C. The ABCs of immunosuppression. Med. Clin. North Am., 2016, 100(3), 505-518. doi: 10.1016/j.mcna.2016.01.003 PMID: 27095642
- Takahashi, J. Preclinical evaluation of patient-derived cells shows promise for Parkinsons disease. J. Clin. Invest., 2020, 130(2), 601-603. doi: 10.1172/JCI134031 PMID: 31929191
- Kikuchi, T.; Morizane, A.; Doi, D. Human iPS cell-derived dopaminergic neurons function in a primate Parkinsons disease model. Nature, 2017, 548(7669), 592-596. doi: 10.1038/nature23664 PMID: 28858313
- Desgres, M.; Menasché, P. Clinical translation of pluripotent stem cell therapies: Challenges and considerations. Cell Stem Cell, 2019, 25(5), 594-606. doi: 10.1016/j.stem.2019.10.001 PMID: 31703770
- Majhail, N.S.; Mau, L.W.; Denzen, E.M.; Arneson, T.J. Costs of autologous and allogeneic hematopoietic cell transplantation in the United States: A study using a large National Private Claims Database. Bone Marrow Transplant., 2013, 48(2), 294-300. doi: 10.1038/bmt.2012.133 PMID: 22773126
- Fričová, D.; Korchak, J.A.; Zubair, A.C. Challenges and translational considerations of mesenchymal stem/stromal cell therapy for Parkinsons disease. NPJ Regen. Med., 2020, 5(1), 20. doi: 10.1038/s41536-020-00106-y PMID: 33298940
- Yamanaka, S. Induced pluripotent stem cells: Past, present, and future. Cell Stem Cell, 2012, 10(6), 678-684. doi: 10.1016/j.stem.2012.05.005 PMID: 22704507
- Tiklová, K.; Björklund, Å.K.; Lahti, L. Single-cell RNA sequencing reveals midbrain dopamine neuron diversity emerging during mouse brain development. Nat. Commun., 2019, 10(1), 581. doi: 10.1038/s41467-019-08453-1 PMID: 30718509
- Liu, K.; Ji, K.; Guo, L. Mesenchymal stem cells rescue injured endothelial cells in an in vitro ischemiareperfusion model via tunneling nanotube like structure-mediated mitochondrial transfer. Microvasc. Res., 2014, 92, 10-18. doi: 10.1016/j.mvr.2014.01.008 PMID: 24486322
- Guo, X.; Tang, L.; Tang, X. Current developments in cell replacement therapy for parkinsons disease. Neuroscience, 2021, 463, 370-382. doi: 10.1016/j.neuroscience.2021.03.022 PMID: 33774124
Қосымша файлдар
